Cargando…
Development of Irinotecan Liposome Armed with Dual-Target Anti-Epidermal Growth Factor Receptor and Anti-Fibroblast Activation Protein-Specific Antibody for Pancreatic Cancer Treatment
Pancreatic cancer is one of the most common causes of death in Taiwan. Previous studies have shown that more than 90% of pancreatic cancer cells presented epidermal growth factor receptor (EGFR) cell marker, and this marker is thought to be important as it is related to activation of cancer cell pro...
Autores principales: | Lin, Hung-Jun, Liang, Tien-Li, Chang, Yao-Yuan, Liu, Der-Zen, Fan, Jia-Yu, Roffler, Steve R., Lin, Shyr-Yi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227843/ https://www.ncbi.nlm.nih.gov/pubmed/35745775 http://dx.doi.org/10.3390/pharmaceutics14061202 |
Ejemplares similares
-
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020) -
Correction to: Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
por: Frampton, James E.
Publicado: (2020) -
Liposomal Irinotecan Shows a Larger Therapeutic Index than Non-liposomal Irinotecan in Patient-Derived Xenograft Models of Pancreatic Cancer
por: Barbier, Sandrine, et al.
Publicado: (2023) -
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
por: Yu, Kenneth H., et al.
Publicado: (2023) -
Pre-existing anti-polyethylene glycol antibody reduces the therapeutic efficacy and pharmacokinetics of PEGylated liposomes
por: Hsieh, Yuan-Chin, et al.
Publicado: (2018)